Taking these factors into account, we developed a CRISPR-based gene knockout method to target A2AR, CBLB, CD96, and KLRC1 (NKG2A) genes to evaluate their antitherapeutic role in AML and B-ALL cancer. The gene discussed is CBLB; the disease is acute myeloid leukemia.